Novel Co-Admin of CAR T Cells Achieves 99% Remission in Leukemia
A novel approach in which two products were co-administered achieved a 99% complete response rate in children with relapsed or treatment-resistant B-cell acute lymphoblastic leukemia (B-ALL).
In this trial, the largest study to date of a CAR T-cell therapy for such patients, the researchers co-administered two CAR T-cell therapies, one targeting CD19 and the other targeting CD22.
The results showed that 192 of 194 patients (99%) achieved a complete remission.
The combined overall 12-month event-free survival was 73.5%.
The study was published online on November 8 in the Journal of Clinical Oncology.
Vous désirez lire la suite de cet article ?
Inscrivez-vous